Research Stage 2 Delayed

July 31, 2020

Dear UMB Community, 

University of Maryland, Baltimore (UMB) Interim President Bruce E. Jarrell, MD, FACS, announced in a recent communication that the University would initiate Stage 1 for clinical and community-based human subjects research on July 20 and if all went well, we would initiate Stage 2 on Aug. 3.  We are now operating in Stage 1.
 
Today, based on a recommendation from the COVID-19 Research Advisory Task Force, Dr.  Jarrell has decided to delay the decision on the start of Stage 2 for an additional two weeks.  The move to Stage 2 for clinical and community-based human subjects research will be re-evaluated on Aug. 17, 2020.
 
This delay will allow us to continue to assess the implementation and execution of Stage 1 and to monitor the status of the pandemic in the region and in Baltimore City.
 
As a reminder, Stage 1 allows for continuation of minimal-risk studies that are remote or no contact, and also allows for research with potential for direct benefit to the research subject requiring in-person visits at UMB-related facilities. 
 
Stage 2 continues activities in Stage 1 and also allows for studies that do not have the potential for direct benefit to the research subjects requiring in-person visits at UMB-related facilities. 
 
The Guidelines for Resuming Human Subjects Research can be found here.
 
If you have questions or need more information, please contact Julie Doherty,DM, MSN, director, Human Research Protections Program, or Robert Rosenthal, MD, chair, Institutional Review Board.
 
Sincerely,
 
Laurie E. Locascio, PhD
Vice President for Research, University of Maryland
Chair, UMB Research Advisory Task Force
 
Margaret M. McCarthy, PhD
Professor and Chair, Department of Pharmacology, University of Maryland School of Medicine 
Deputy Chair, UMB Research Advisory Task Force